ARROW is comparable to a recent report on AEs in NSCLC patients, which demonstrated that pralsetinib induced hematologic toxicities, such as neutropenia, lymphopenia, and anemia, compared to selpercatinib, in addition to hypertension, elevated alanine transaminase (ALT), and aspartate transaminase (AST). The gene discussed is GPT; the disease is anemia.